logo-loader
viewDyadic International Inc

Dawson James Securities initiates coverage on Dyadic International with a Buy rating

Analyst Jason H Kolbert said the company’s C1 gene expression platform is more efficient than competing methods

Gene symbol in pill
Based on the Myceliophthora thermophila fungus, Dyadic’s platform produces enzymes and proteins

Analysts at Dawson James Securities initiated coverage Monday on Dyadic International Inc (NASDAQ:DYAI) with a Buy rating citing the effectiveness of the biotechnology company’s C1 gene expression platform.

The boutique investment bank also set a $14 price target for Dyadic which currently trades in the $6.61 range.

In a note to clients, Dawson James analyst Jason H Kolbert said the Jupiter, Florida, biotechnology company’s C1 platform specializes in enzymes and protein production more “efficiently than competing methods.”

“Starting out as a gene expression platform for the production of commercial quantities of industrial enzymes and proteins, C1 has proven to have the ability to produce greater quantities of enzymes and proteins in large quantities with high priority all while maintaining a relatively low cost,” said Kolbert.

READ: Noble Research repeats Outperform rating and $9 target on Dyadic following second quarter results

“C1 is now poised to branch out into the biomedical market, aiming to develop products such as innovative vaccines and drugs, biosimilars and biobetters,” he added.

Dyadic leverages its proprietary C1 expression system — a fungal expression technology for producing enzymes — to help bring biologic vaccines, therapeutic enzymes, proteins, biosimilars and drugs to market faster and at a lower cost.

Dyadic has patented its proprietary filamentous fungus, Myceliophthora thermophila, nicknamed C1 and the associated molecular tools used to engineer the C1 cells to express and manufacture large volumes of low-cost biologic products such as enzymes and proteins. The C1 fungus is a living cell that has been bioengineered by Dyadic scientists for more than two decades.

“Dyadic’s C1 technology is aimed at improving the development and manufacturing of human and animal vaccines (such as virus-like particles and antigens), monoclonal antibodies (mAbs), Bi-specific antibodies, Fab antibody fragments, Fc-Fusion proteins, and other therapeutic enzymes and proteins,” said Kolbert.

“Dyadic’s exclusive sublicensing rights allow for low risk, high reward royalties with other companies,” he added.

A wide range of applications

The analyst said C1’s ability to “efficiently produce” enzymes allows Dyadic to develop this platform for a “wide range of major markets.” Dyadic plans on expanding C1’s industrial enzyme production in areas such as animal feed, paper production, and textiles.

“Dyadic has non-exclusive license agreements for C1 to Codexis, Royal Dutch Shell, Cosan, and Raizen with the goal of utilizing C1 as a platform to develop and manufacture biofuels and chemicals, such as ethanol, from agricultural feedstocks,” noted Kolbert.

“At the same time, (there is) a research and commercialization collaboration agreement with Serum Institute of India for the development and manufacture of up to 12 antibodies and vaccines using Dyadic's C1 gene expression system,” he added.

Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sublicense for each of the proteins expressed from its C1 technology. In return for these sublicenses, Dyadic will receive research funding, milestone payments, and royalties for 15 years from the date of the first commercial sale.

“C1 is a natural fit for collaboration with many pharma, biotech, and biosimilars, as the platform can be adapted to produce whatever enzyme each company would need,” Kolbert noted. "A few partnerships out of the many prospective biotech companies would be massively impactful for Dyadic.”

The Dupont deal

The analyst pointed out that in 2015, Dyadic sold an industrial business segment to Dupont for $75 million.

“The company has come a long way in the four decades that its founder and CEO, Mark Emalfarb, founded a pumice stone process for blue jeans,” said Kolbert.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Quick facts: Dyadic International Inc

Price: 5.74 USD

NASDAQ:DYAI
Market: NASDAQ
Market Cap: $155.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Dyadic 'advancing the ball down the field' with Wall St, and its C1 gene...

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb sat down with Proactive at the BIO Investor Forum in San Francisco.  Analysts at Dawson James Securities recently initiated coverage on Dyadic with a Buy rating citing the effectiveness of the biotechnology company’s C1 gene...

3 weeks ago

3 min read